Website: ethosbiosciences.com | LinkedIn: linkedin.com/company/ethos-biosciences
Accurate. Repeatable. Easy to Use.
How Ethos Biosciences builds diagnostic tools that help researchers study kidney disease, diabetes, and more
At a glance
- Company: Ethos Biosciences (ethosbiosciences.com)
- Founded: 2018, as a subsidiary of Ott Scientific. Based in southern New Jersey
- Focus: ELISA kits, reagents, antibodies, stains, and assay components for clinical and research laboratories
- Research areas: Nephrology, diabetes, cardiology, and oxidative stress
- Working with PSG on: Fractional commercialization services
Building on three decades of science
Ethos Biosciences was formed in 2018 to drive healthcare innovation through better diagnostic tools for scientists and practitioners. That same year, it acquired the Exocell diagnostic operation in Philadelphia. Exocell was founded in 1988 by Dr. Margo Cohen to explore diagnostic and therapeutic solutions for diabetes.
Today, Exocell, now part of Ethos, brings more than 30 years of expertise to products used in kidney disease and diabetes research worldwide.
Products researchers rely on
- ELISA kits for detecting proteins, antibodies, antigens, and hormones in nephrology, diabetes, cardiology, and oxidative stress research
- Reagents and antibodies, including monoclonal antibodies and hemoglobin fractions for experimental and clinical research
- Diagnostic reagents, stains, and assay components for clinical and research labs
- Custom testing and assay development for specialized research needs
Ethos’ mission is simple: provide accurate, repeatable, easy-to-use products that drive better healthcare outcomes.